MFDS to Hold Key Policy Briefing on 'Quasi-Drugs' on the 21st

[Asia Economy Reporter Lee Gwan-ju] The Ministry of Food and Drug Safety announced on the 8th that it will hold the '2023 Quasi-Drug Policy Briefing Session' on the 21st at the LW Convention in Seoul for quasi-drug manufacturers and importers.

At this briefing session, the following will be covered: ▲ 2023 key policy directions for quasi-drugs ▲ amendments to the 'Pharmaceutical Affairs Act' related to quasi-drugs ▲ 2023 quasi-drug manufacturing and distribution management plans ▲ promotion of voluntary adoption of quasi-drug GMP ▲ quasi-drug approval procedures.

Those wishing to attend the briefing session must apply for pre-registration by the 14th. A total of 140 participants will be admitted on a first-come, first-served basis (80 from the Korea Pharmaceutical and Bio-Pharma Manufacturers Association, 60 from the Korea Pharmaceutical Traders Association), and the policy briefing materials will be posted later on the Ministry of Food and Drug Safety website.

An official from the Ministry of Food and Drug Safety stated, "We expect this policy briefing session to help the industry better understand the safety management policy directions for quasi-drugs," adding, "We plan to continuously create opportunities for communication with companies in the future."

This content was produced with the assistance of AI translation services.